Invesco
MAZE

Invesco’s Maze Therapeutics MAZE Stock Holding History

Invesco’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.58M Sell
86,419
-47,614
-36% -$2.1M ﹤0.01% 2433
2025
Q4 		$5.55M Buy
134,033
+1,971
+1% +$67.7K ﹤0.01% 2200
2025
Q3 		$3.42M Buy
132,062
+113,632
+617% +$1.92M ﹤0.01% 2394
2025
Q2 		$226K Sell
18,430
-2,122
-10% -$22.1K ﹤0.01% 3478
2025
Q1 		$226K Buy
+20,552
New +$247K ﹤0.01% 3460

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco's MAZE Position: Q1 2026 in Review

Invesco reduced its Maze Therapeutics (MAZE) stake by 36% in Q1 2026, selling an estimated $2.1M and leaving 86,419 shares worth $2.58M. The position accounts for ﹤0.01% of the portfolio, ranked #2433.

Invesco first reported a position in MAZE in Q1 2025 and has held it in 5 quarters since. The position peaked at $5.55M in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Invesco held 86,419 shares of Maze Therapeutics worth $2.58M as of Q1 2026.
  • Invesco sold 47,614 Maze Therapeutics shares in Q1 2026, an estimated $2.1M.
  • Maze Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2433 holding.
  • Invesco first reported a position in Maze Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Invesco's Maze Therapeutics position peaked at $5.55M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.